Alpha 2.0
Login Register
» Authors » Milensu Shanyinde

Milensu Shanyinde

Explore the profile of Milensu Shanyinde including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 1216
Followers 0
Related Specialties
General Medicine
Public Health
Infectious Diseases
Top 10 Co-Authors
Ly-Mee Yu
Christopher C Butler
Massimo Puoti
Victoria Harris
Antonella dArminio Monforte
Mahendra G Patel
Alessandro Cozzi-Lepri
Jienchi Dorward
Mark Fitzgerald
Duncan Richards
Published In
PLoS One
BMC Med Res Methodol
J Infect
J Clin Oncol
Pathog Glob Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hobbs F, Gbinigie-Thompson O, Shanyinde M, Yu L, Harris V, Dorward J, et al.
J Infect . 2024 Aug; 89(4):106248. PMID: 39216829
Background: Evidence for the effect of favipiravir treatment of acute COVID-19 on recovery, hospital admissions and longer-term outcomes in community settings is limited. Methods: In this multicentre. open-label, multi-arm, adaptive...
2.
FOUND Trial: randomised controlled trial study protocol for case finding of obstructive sleep apnoea in primary care using a novel device
Miller M, Yu L, Ali A, Apenteng P, Auguste P, Dale J, et al.
BMJ Open . 2024 Jul; 14(7):e090000. PMID: 39059802
Introduction: Obstructive sleep apnoea (OSA) is a common, but underdiagnosed, sleep disorder. If untreated, it leads to poor health outcomes, including Alzheimer's disease, cancer, cardiovascular disease and all-cause mortality. Our...
3.
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hayward G, Yu L, Little P, Gbinigie O, Shanyinde M, Harris V, et al.
J Infect . 2024 Mar; 88(4):106130. PMID: 38431155
Background: The evidence for whether ivermectin impacts recovery, hospital admissions, and longer-term outcomes in COVID-19 is contested. The WHO recommends its use only in the context of clinical trials. Methods:...
4.
Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial
Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman P, et al.
JAMA . 2023 Nov; 330(20):1991-1999. PMID: 37950919
Importance: Pregnancy hypertension results in adverse cardiac remodeling and higher incidence of hypertension and cardiovascular diseases in later life. Objective: To evaluate whether an intervention designed to achieve better blood...
5.
Clinical diagnosis of SARS-CoV-2 infection: An observational study of respiratory tract infection in primary care in the early phase of the pandemic
van der Velden A, Shanyinde M, Bongard E, Bohmer F, Chlabicz S, Colliers A, et al.
Eur J Gen Pract . 2023 Oct; 29(1):2270707. PMID: 37870070
Background: Early in the COVID-19 pandemic, GPs had to distinguish SARS-CoV-2 from other aetiologies in patients presenting with respiratory tract infection (RTI) symptoms on clinical grounds and adapt management accordingly....
6.
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Dorward J, Yu L, Hayward G, Saville B, Gbinigie O, Van Hecke O, et al.
Br J Gen Pract . 2022 Apr; 72(720):e446-e455. PMID: 35440469
Background: Colchicine has been proposed as a COVID-19 treatment. Aim: To determine whether colchicine reduces time to recovery and COVID-19-related admissions to hospital and/or deaths among people in the community....
7.
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy
Brancaccio G, Shanyinde M, Puoti M, Gaeta G, Monforte A, Vergori A, et al.
Pathog Glob Health . 2022 Mar; 117(2):181-189. PMID: 35249472
Hepatitis Delta virus (HDV) causes severe liver disease. Due to similarities in transmission routes, persons living with HIV (PLWH) are at risk of HDV infection. This analysis investigates the prevalence...
8.
PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
Au-Yeung S, Griffiths J, Roberts S, Edwards C, Yu L, Bogacz R, et al.
Evid Based Ment Health . 2021 Nov; 25(2):77-83. PMID: 34810175
Introduction: Clinical depression is usually treated in primary care with psychological therapies and antidepressant medication. However, when patients do not respond to at least two or more antidepressants within a...
9.
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Butler C, Ellis C, Folegatti P, Swayze H, Allen J, Bussey L, et al.
Vaccines (Basel) . 2021 Aug; 9(8). PMID: 34451976
Background: Pre-existing T cell responses to influenza have been correlated with improved clinical outcomes in natural history and human challenge studies. We aimed to determine the efficacy, safety and immunogenicity...
10.
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Yu L, Bafadhel M, Dorward J, Hayward G, Saville B, Gbinigie O, et al.
Lancet . 2021 Aug; 398(10303):843-855. PMID: 34388395
Background: A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether...